Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Who May Qualify: - Patient understands the procedures and requirements and is willing and able to give willing to sign a consent form for full participation in the study. - Previously healthy adults, male or female, aged 18 to 60 years at time of consent with early symptomatic COVID-19 - SARS-CoV-2 positive by lateral flow antigen test OR a positive PCR test for SARS-CoV-2 within the last 24hrs with a Ct value of less than 25 (all viral targets) - Symptoms of COVID-19 (including fever, or history of fever) for less than 4 days (96 hours). - Oxygen saturation ≥96% measured by pulse-oximetry at time of screening. - Able to walk unaided and unimpeded in ADLs - Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits Who Should NOT Join This Trial: The patient may not enter the study if ANY of the following apply: - Taking any concomitant medications or drugs (see appendix 4)† - Presence of any chronic illness/ condition requiring long term treatment, or other significant comorbidity (e.g. diabetes, obesity but see appendix 4 for the full list) - Laboratory abnormalities discovered at screening (see appendix 4) - For females: pregnancy, actively trying to become pregnant, or lactation - Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics (see appendix 4) - Currently participating in another COVID-19 therapeutic or vaccine trial - Evidence of pneumonia (although imaging is NOT required) - healthy women on the oral contraceptive pill are eligible to join the study Always talk to your doctor about whether this trial is right for you.